MANAMA: The National Health Regulatory Authority (NHRA) has approved Regn-Cov2 for emergency use to treat Covid-19 cases with mild to moderate symptoms.

Regn-Cov2 developed by Regeneron and Roche, contains a combination of Casirivimab and Imdevimab (monoclonal antibodies) and is projected to block viral attachment and entry into human cells.

It also received emergency use approval from the US’ FDA to treat Covid-19 in non-hospitalised adults and adolescents aged 12 years and older, who weigh at least 40kg, and those in the high-risk category.

The drug also received a positive review from the European Medicines Agency after their analysis of its quality, safety and efficacy.

It has been added to the list of approved drugs by Bahrain for treatment of Covid-19 using antibody testing technology.

The approval reflects the kingdom’s commitment to provide the latest Covid-19 medicines and treatments for all, which would prevent severity of active cases, and reduce the risk to enter intensive care.

© Copyright 2020 www.gdnonline.com

Copyright 2021 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.